INTRODUCTION AND OBJECTIVES: Partial nephrectomy (PN) is considered a strong (imperative/relative) indication for patients with stage 3 chronic kidney disease [(CKD), estimated glomerular filtration rate (eGFR)<60 ml/min/1.73m2] and is considered elective for patients with higher GFR. Change in GFR (DGFR) is less for PN compared to radical nephrectomy (RN), and patients with stage 2 CKD (eGFR 60-89) may be at increased risk for postoperative renal decline to thresholds of increased risk. We compared renal function and survival outcomes in patients with baseline stage 2 CKD who underwent PN or RN.
METHODS: International multicenter retrospective analysis of patients with baseline stage 2 CKD who underwent PN or RN from 1987-2015. Demographics, disease characteristics, survival and renal function outcomes were recorded. Patients were stratified into baseline Stage 2a CKD and Stage 2b CKD (GFR 60-74.9) for analysis. Primary outcome was DGFR at last follow up. Secondary outcomes included occurrence of GFR<45, a risk factor for poor survival outcomes, and overall survival (OS). Cox proportional hazard regression, Kaplan Meier analysis, and multivariable (MV) regression for risk factors associated with outcomes was performed.
RESULTS: 1460 patients were analyzed (mean age 61.9 years, median follow up 46 months). 49.3% underwent PN/50.7% underwent RN, and 49.5% were Stage 2a CKD (n¼723) while 50.5% were Stage 2b CKD (n¼737). Mean DGFR was greater for RN than PN overall (-12.5 vs. -6.5, p<0 .001), in stage 2a CKD (-12.9 vs. -10.0, p<0.001), and stage 2b CKD (-11.9 vs. -2.9, p<0.001). Cox proportional hazard regression for GFR<45 noted negative effect for RN overall (HR 1.78, p<0.001), in Stage 2a CKD (HR 1.88, p¼0.019), and in Stage 2b CKD (HR 1.74, p¼0.002). On MV regression for GFR<45, Stage 2b CKD (OR 1.70, p<0.001) and RN (OR 1.47, p¼0.028) were independent risk factors. MV regression for OS was worse for RN overall (OR 2.93, p<0.001), in Stage 2a CKD (OR 3.12, p<0.001), and in 2b CKD (OR 2.77, p<0.001).
CONCLUSIONS: Patients with baseline Stage 2 CKD undergoing RN are at increased risk of GFR decline, including the threshold of GFR<45, and worsened OS. For patients with Stage 2 CKD, PN may be considered a relative indication and should be prioritized when appropriate. cell carcinoma, treatment of larger renal tumors is controversial. We evaluated the oncological outcomes and perioperative complications after radical and partial nephrectomy for renal cell carcinoma 4 cm.
Source of
METHODS: We retrospectively analyzed the data of 2,373 patients surgically treated for non-metastatic RCC with clinical T1b or T2 ( 4 cm). The propensity scores for surgery type were calculated and the partial group was matched to the radical group in a 1:3 ratio. The oncological outcomes were compared using Kaplan-Meier analysis and multivariate Cox regression models were utilized to identify the independent predictors of progression-free, cancer-specific, and overall survival.
RESULTS: All differences in preoperative clinical characteristics disappeared after matching. There were no significant differences in progression-free, cancer-specific, or overall survival between the partial and radical groups in the matched cohort. The patients 0 age, tumor size, cellular grade, and pathologic stage were independent predictors for all three survival outcomes. However, early complications (< 30 days postoperative) were significantly more common in the partial group (p < 0.001). In a subgroup analysis of the patients with clinical T2 stage, there were no significant differences in all three survival outcomes.
CONCLUSIONS: The partial and radical nephrectomy groups had equivalent oncological outcomes. Although the early complication rate was significantly higher after partial nephrectomy, it should be considered as a valuable treatment option even in patients with clinical T1b or higher renal cell carcinoma. METHODS: Retrospective study of 830 consecutive cases of PN done between 2007 and 2015 at a single institution. Patient demographics, and pathological characteristics were correlated with recurrence patterns (overall, local and distant) and overall survival (OS) using Kaplan-Meier and cox regression analyses. Differences in the recurrence patterns were evaluated. RESULTS: Median age was 61 years, and median tumor size was 3.1 cm. Overall, 11.6% of tumors were pT3 stage, 39.3% were high grade, 2.9% had lymphovascular invasion, and 7.1% had positive Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e955 margins. Median follow up was 36 months. INTRODUCTION AND OBJECTIVES: pT3a disease is known to represent a poor prognostic factor in renal cell carcinoma (RCC) with an approximate four-fold increased risk for recurrence regardless of size when compared to pT1 disease. The impact of incidental pT3a upstaging in patients undergoing partial nephrectomy (PNx) for cT1 disease, however, is not well defined.
METHODS: A retrospective chart review was completed at the University of Michigan and Moffitt Cancer Center to identify patients who underwent PNx between 1996-2015 for cT1 RCC with subsequent pathologic upstaging to pT3a disease. Patients with pT3a disease were compared to controls who underwent PNx for cT1 disease with final pathology confirming pT1 disease. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method.
RESULTS: A total of 95 patients with pT3a upstaging were identified and compared to 1164 controls. Median follow up in our series was 38.2 (IQR 11.6-56.8) months. Following PNx, 20 (21%) patients with incidental pT3a upstaging suffered disease recurrence at a median of 28.7 months (IQR 10.3-43.5), consisting of 4 (4%) local recurrences and 17 (18%) distant metastases. In comparison, 8 (0.7%) controls suffered disease recurrence at a median of 46.6 months . In patients with pT3a disease, the 5-and 8-year RFS was 71% and 59%, compared to 88% and 78% in controls (p<0.0001). CSS was also significantly different between cohorts, with pT3a patients experiencing a 5-and 8-year CSS of 92% and 79%, compared to 99% and 98% in controls (p¼0.001). Kaplan-Meijer curves are depicted in Figure  1 . There were a total of 7 (7%) RCC related deaths, which occurred at a median of 28.5 months (IQR 9.3-54.3) in the pT3a cohort, while there were 5 (0.4%) RCC related deaths at a median of 96.5 months (IQR 56.9-96.9) in those with final pT1 disease.
CONCLUSIONS: The data presented here suggests that patients with cT1 disease and incidental pT3a upstaging following PNx experience a significantly reduced RFS and CSS compared to those with final pT1 disease, and thus may benefit from modified follow up protocols or early adjuvant therapies.
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MP72-07 HISTOPATHOLOGIC ANALYSIS OF TUMOR BED AFTER IN VITRO TUMOR ENUCLEATION ON RADICAL NEPHRECTOMY SPECIMEN
Qun Lu*, Changwei Ji, Xiaozhi Zhao, Guangxiang Liu, Hongqian Guo, Nanjing, China, People's Republic of INTRODUCTION AND OBJECTIVES: In recent years, large series of tumor enucleation (TE) for renal masses have showed equivalent functional and oncological results compared with standard partial nephrectomy. However, few objective assessments and pathologic evidence of enucleation tumor bed have been reported. This study was designed to assess the feasibility and histopathologic safety of tumor enucleation for renal cell carcinoma, through histopathologic analysis of the tumor bed after in vitro tumor enucleation.
METHODS: We studied 246 radical nephrectomy specimens for clinical T1 RCC in our institution, from January 2013 to December 2015. Immediately after the kidney was excised, the tumor of radical specimen was enucleated in vitro in the same fashion as open or e956 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
